secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001753926-25-000966
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical reports exenatide implant cuts liver fat 82% in obese mice
-------------------------------------------------------------------------

- Exenatide implant reduced liver fat by 82% vs sham in high-fat diet obese mice after 12 weeks (Oil Red O staining).
- Exenatide delivered via NanoPortal technology showed durable body weight reduction in rats over 105-140 days.
- Findings from corporate slide presentation furnished as Exhibit 99.1; no material financial updates.
- Vivani is developing NPM-119 (exenatide implant) for metabolic indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625000966/0001753926-25-000966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625000966/vani-20250617.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer